A Personalized Medicine Approach Using Clinical Utility Index and Exposure-Response Modeling Informed by Patient Preferences Data.

Under this scenario, the predicted pCUI dose was 150 mg q.d., an approved dosage for elagolix, where DYSP efficacy did not reach statistical significance. 5 Although statistical significance of the 150 mg q.d. for DYSP was not achieved at month 6, 12 the exposure‐response time‐course model for this end point suggests a possible benefit compared with placebo when the overall data are considered ( Figure 1 ).

also in 111,027 other papers